on May 27, 2004
Published online before print May 27, 2004, doi: 10.1161/01.STR.0000131656.47979.39
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 7, 2003
From the Departments of Neurology (M.C., J.S., A.D.) and Neuroradiology (S.P.), Hospital Universitari Doctor Josep Trueta, Girona, Spain; and the Department of Neurology, Hospital Clínico Universitario de Santiago, Santiago de Compostela (R.L., M.B., J.C.), Spain. * To whom correspondence should be addressed. E-mail: nrl.mcastellanos{at}htrueta.scs.es.
Background and Purpose--Elevated plasma levels of cellular fibronectin (c-Fn) reflect vascular damage, so c-Fn might be a marker of secondary bleeding risk in cerebral ischemia. We investigated whether high plasma levels of c-Fn were associated with hemorrhagic transformation (HT) after treatment with tissue plasminogen activator (tPA) in patients with acute stroke. Methods--Eighty-seven patients (mean age: 67±12) received tPA after the ECASS II criteria (mean time to infusion: 160±46 minutes; median NIHSS: 12). HT and hypodensity volume were studied on computed tomography (CT) performed 24 to 36 hours after treatment. HT was classified according to the ECASS II definitions. c-Fn and matrix metalloproteinase 9 (MMP-9) levels were determined by ELISA in blood samples obtained before treatment and in 30 healthy subjects. Results--HT was found in 26 patients (30%); 15 patients had hemorrhagic infarction type 1 (HI-1), 7 had HI-2, and 4 had parenchymal hemorrhage (PH). Median c-Fn concentrations were 1.3, 1.7, 4.2, 5.4, and 7.3 µg/mL in controls, non-HT, HI-1, HI-2, and PH groups, respectively (P<0.001); median MMP-9 values were 54, 87, 154, 176, and 225 ng/mL (P<0.001). Logistic regression analysis showed that only c-Fn plasma levels remained independently associated with HT after adjusting for potential confounders (OR, 2.1; 95% CI, 1.3 to 3.4; P=0.002). Similar results were obtained in the 71 patients treated within 3 hours. Conclusions--High plasma c-Fn levels are significantly associated with subsequent HT in stroke patients treated with tPA, so plasma c-Fn determinations might be useful in clinical practice to improve the risk/benefit ratio of thrombolytic treatment.
Revised on March 9, 2004
Accepted on April 6, 2004
Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke
Mar Castellanos MD*;
Key words: stroke • stroke, acute • hemorrhage • thrombolytic therapy
This article has been cited by other articles:
 |
|
 |
|
  C. Foerch, J. Montaner, K. L. Furie, M. M. Ning, and E. H. Lo Invited Article: Searching for oracles?: Blood biomarkers in acute stroke Neurology, August 4, 2009; 73(5): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, J. Hendren, X.-J. Qin, and K. J. Liu Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia Stroke, July 1, 2009; 40(7): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Derex and N Nighoghossian Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Chauhan, J. Kisucka, M. R. Cozzi, M. T. Walsh, F. A. Moretti, M. Battiston, M. Mazzucato, L. De Marco, F. E. Baralle, D. D. Wagner, et al. Prothrombotic Effects of Fibronectin Isoforms Containing the EDA Domain Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A.B. Klemmt, J. G. Carver, P. Koninckx, E. J. McVeigh, and H. J. Mardon Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: towards a mechanistic model for endometriosis progression Hum. Reprod., December 1, 2007; 22(12): 3139 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Foerch, M. T. Wunderlich, F. Dvorak, M. Humpich, T. Kahles, M. Goertler, J. Alvarez-Sabin, C. W. Wallesch, C. A. Molina, H. Steinmetz, et al. Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke Stroke, September 1, 2007; 38(9): 2491 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castellanos, T. Sobrino, M. Millan, M. Garcia, J. Arenillas, F. Nombela, D. Brea, N. Perez de la Ossa, J. Serena, J. Vivancos, et al. Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study Stroke, June 1, 2007; 38(6): 1855 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Khatri, L. R. Wechsler, and J. P. Broderick Intracranial Hemorrhage Associated With Revascularization Therapies Stroke, February 1, 2007; 38(2): 431 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rodriguez-Yanez, M. Castellanos, M. Blanco, M. Millan, F. Nombela, T. Sobrino, I. Lizasoain, R. Leira, J. Serena, A. Davalos, et al. Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke. Neurology, October 10, 2006; 67(7): 1172 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gonzalez-Conejero, I. Fernandez-Cadenas, J. A. Iniesta, J. Marti-Fabregas, V. Obach, J. Alvarez-Sabin, V. Vicente, J. Corral, J. Montaner, and for the Proyecto Ictus Research Group Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients Stroke, September 1, 2006; 37(9): 2288 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ning, K. L. Furie, W. J. Koroshetz, H. Lee, M. Barron, M. Lederer, X. Wang, M. Zhu, A. G. Sorensen, E. H. Lo, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke Neurology, May 23, 2006; 66(10): 1550 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cocho, M. Borrell, J. Marti-Fabregas, J. Montaner, M. Castellanos, Y. Bravo, L. Molina-Porcel, R. Belvis, J.-A. Diaz-Manera, A. Martinez-Domeno, et al. Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator Stroke, April 1, 2006; 37(4): 996 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bosche, G. F. Hamann, C. Dohmen, R. Graf, J. Serena, M. Castellanos, J. Castillo, M. Blanco, and A. Davalos There Is More to it Than: the Greater the Infarction Volume, the More Probable Is a Malignant MCA Infarction Stroke, March 1, 2006; 37(3): 762 - 764. [Full Text] [PDF]
|
|
|
|
|
|
S. Juvela and C. S. Kase Advances in Intracerebral Hemorrhage Management Stroke, February 1, 2006; 37(2): 301 - 304. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Allard, P. R. Burkhard, P. Lescuyer, J. A. Burgess, N. Walter, D. F. Hochstrasser, and J.-C. Sanchez PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the Early Diagnosis of Stroke Clin. Chem., November 1, 2005; 51(11): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Serena, M. Blanco, M. Castellanos, Y. Silva, J. Vivancos, M. A. Moro, R. Leira, I. Lizasoain, J. Castillo, and A. Davalos The Prediction of Malignant Cerebral Infarction by Molecular Brain Barrier Disruption Markers Stroke, September 1, 2005; 36(9): 1921 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Laudanski, J. Szamatowicz, H. Laudanska, M. Castellanos, J. Castillo, and A. Davalos Cellular-Fibronectin and Matrix Metalloproteinase-9 in Patients With Stroke Stroke, January 1, 2005; 36(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
Y. Silva, R. Leira, J. Tejada, J. M. Lainez, J. Castillo, A. Davalos, and by the Stroke Project, Cerebrovascular Diseases Gr Molecular Signatures of Vascular Injury Are Associated With Early Growth of Intracerebral Hemorrhage Stroke, January 1, 2005; 36(1): 86 - 91. [Abstract] [Full Text] [PDF]
|
|